14 | ֿ | Evaluating risk of problems from Beers Criteria medication combinations | BioEMR |
23 | ֿ | Parkinsons disease Genomic Analysis | Seminar |
21 | ֿ | Applying modified method of candidate SAG extraction | TopicSem | |
21 | ֿ | Star allele calling for UKBB | BioEMR |
06 | ֿ | Synthetic association analysis for tacrolimus response | TopicSem | |
06 | ֿ | SWEDEGENE-a Swedish nation-wide DNA sample collection for pharmacogenomic studies of serious adverse drug reactions | BioEMR |
03 | ֿ | Detection of variants contributing to synthetic association in Parkinsons disease | TopicSem |
21 | ֿ | Evaluation of candidate SAGs contributing to Parkinsons disease | TopicSem |
05 | ֿ | Utility of extended Stargazer for calling star alleles with WGS data | BioEMR | |
24 | ֿ | Characterizing pharmacogenomic-guided medication use with a clinical data repository | J.Club |
08 | ֿ | Network, transcriptomic and genomic features differentiate genes relevant for drug response | J.Club | |
17 | ֿ | Candidate SAG characteristic examination based on drug-gene interaction status | TopicSem |
10 | ֿ | Evaluation of gene deleteriousness scores in the confirmation synthetic association signals | TopicSem |
29 | ֿ | Quantifying the impact of rare and ultra-rare coding variation across the phenotypic spectrum | J.Club |
05 | ֿ | Interpretation of PGx variant candidate SAGs | TopicSem |
14 | ֿ | Gene set annotation for genes synthetically associated with PGx variants | SysBiol | |
16 | ֿ | Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing | J.Club |
11 | ֿ | Extracting variants associated to drug response from the NHGRI GWAS Catalog | SysBiol | |
13 | ֿ | Analysis of synthetically associated genes to PGx variants | TopicSem |
05 | ֿ | ADR risk determination according to PGx variant statususing synthetic association | TopicSem |
24 | ֿ | Statistics of updated PGx variants for synthetic association analysis | SysBiol | |
26 | ֿ | ADR risk determination according to PGx variant status using synthetic association | TopicSem |
01 | ֿ | ADR risk determination according to FDA or PREDICT SNP genotype using synthetic association | TopicSem |
23 | ֿ | Chromosomal distribution of variants synthetically associated with pharmacogenomic SNPs | SysBiol |
09 | ֿ | Gene score distribution of genes including or proximate to pharmacogenomic SNPs | TopicSem |
10 | ֿ | South Korean geriatrics on Beers Criteria medications at risk of adverse drug events | TopicSem | |
31 | ֿ | Results of variant-centric approach for MRONJ | SysBiol | |
31 | ֿ | Human BioPathway Databases | SysBiol |
01 | ֿ | Distribution of F10 mutations in the 1000 Genomes phase 3 population | SysBiol | |
10 | ֿ | Finding genomic features that affect drug response | TopicSem |
09 | ֿ | Computational discovery of transcription factors associated with drug response | J.Club | |
11 | ֿ | Assessing drug response based on genetic mutation and expression | TopicSem |
08 | ֿ | Mutations that change drug response due to altered gene expression | TopicSem | |
13 | ֿ | Detecting candidate variants of MRONJ occurrence | SysBiol |
02 | ֿ | Predicting drugs related to treatment failure based on CNVs | TopicSem |
08 | ֿ | Review of very important pharmacogenes in PharmGKB | SysBiol | |
23 | ֿ | Predicting high risk drugs in 1KP based on pharmacogene CNVs | TopicSem |
15 | ֿ | Variant centric analysis for MRONJ | TopicSem | |
20 | ֿ | A prognostic model based on readily available clinical data enriched a pre-emptive pharmacogenetic testing program | J.Club |
06 | ֿ | Finding genetic variants associated with increased risk for BRONJ | TopicSem | |
19 | ֿ | Model on predicting patients likely to benefit from preemptive genotying | SysBiol |
03 | ֿ | Review of pharmacoeconomic analysis methods | SysBiol | |
24 | ֿ | Application of breakeven analysis for preemptive genotyping | SysBiol |
13 | ֿ | Review of pharmacogene-related ADRs in Koreans | SysBiol | |
26 | ֿ | Economic evaluation of preemptive genotyping | TopicSem |
05 | ֿ | Results for preemptive genotyping to prevent adverse drug events | TopicSem | |
11 | ֿ | Trend in predicted number of people with serious AE over year 2011 | SysBiol |
11 | ֿ | Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands | J.Club | |
27 | ֿ | Preemptive genotyping for prevention of drug-related adverse events | TopicSem |
23 | ֿ | Preemptive genotyping for prevention of drug-related adverse events | TopicSem |
20 | ֿ | Preemptive genotyping for prevention of drug-related adverse events | TopicSem | |
22 | ֿ | Statistics of year 2011 HIRA patient and drug data | SysBiol |
10 | ֿ | Review of FDA-approved drugs with pharmacogenomic information in their labeling | SysBiol | |
30 | ֿ | Preemptive genotyping for prevention of drug-related adverse events | TopicSem |
08 | ֿ | Review of Cancer Genome Project database | SysBiol | |
08 | ֿ | Review of Cancer Genome Project database | SysBiol | |
08 | ֿ | Review of Cancer Genome Project database | SysBiol | |
08 | ֿ | Review of Cancer Genome Project database | SysBiol | |
28 | ֿ | Finding genomic factors that regulate drug efficacy | TopicSem |
18 | ֿ | Role and mechanisms of drug targets, enzymes, transporters, and carriers | SysBiol | |
18 | ֿ | Role and mechanisms of drug targets, enzymes, transporters, and carriers | SysBiol | |
29 | ֿ | DGIdb: mining the druggable genome | J.Club |